SHR A 1921
Alternative Names: SHR-1921; SHR-A 1921Latest Information Update: 23 Sep 2025
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Developer Atridia; Suzhou Suncadia Biopharmaceuticals
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ovarian cancer
- Phase II Salivary gland cancer; Solid tumours
Most Recent Events
- 30 May 2025 Efficacy and adverse events data from the phase II trial in Salivary gland cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 30 May 2025 Efficacy and adverse events data from a phase-II clinical trials in Salivary gland cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 13 Sep 2024 Adverse events and efficacy data from a phase-I trial in Solid tumors presented at the 49th European Society for Medical Oncology Congress (ESMO-2024),